# Fosfomycin I.v. for Treatment of Severely Infected Patients

> **NCT02979951** · — · RECRUITING · sponsor: **Infectopharm Arzneimittel GmbH** · enrollment: 1000 (estimated)

## Conditions studied

- Bacterial Infections
- Bone Diseases, Infectious
- Osteomyelitis
- Central Nervous System Bacterial Infections
- Meningitis, Bacterial
- Encephalitis
- Brain Abscess
- Urinary Tract Infections
- Respiratory Tract Infections
- Pneumonia, Bacterial
- Skin Diseases, Bacterial
- Soft Tissue Infections
- Intraabdominal Infections
- Sepsis
- Bacteremia
- Endocarditis, Bacterial

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02979951
- **Lead sponsor:** Infectopharm Arzneimittel GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2016-12
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02979951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02979951, "Fosfomycin I.v. for Treatment of Severely Infected Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02979951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*